Use of Il-17F for the Treatment and/or Prevention of Neurologic Diseases

1 - 31 . (canceled)

32 . A pharmaceutical composition comprising: a) IL-17F or an agonist of IL-17F activity, b) an interferon, osteopontin and/or clusterin and c) one or more pharmaceutically acceptable excipients.

33 . A method for treating a neurologic disease comprising administering to a patient in need thereof an effective amount of a composition comprising IL-17F or an agonist of IL-17F activity.

34 . The method according to claim 33 , wherein said composition further comprises an interferon, osteopontin and/or clusterin.

35 . The method according to claim 33 , wherein the neurologic disease is associated with inflammation.

36 . The method according to claim 35 , wherein the inflammation is neuro-inflammation.

37 . The method according to claim 33 , wherein the neurologic disease is selected from the group consisting of traumatic nerve injury, stroke, demyelinating diseases of the CNS or PNS, neuropathies, neurodegenerative diseases, neurologic disease caused by a congenital metabolic disorder, peripheral neuropathy, diabetic neuropathy, multiple sclerosis (MS), relapsing-remitting multiple sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS) and a demyelinating disease selected from the group consisting of chronic inflammatory multiple sclerosis, demyelinating polyneuropathy (CIDP) and Guillain-Barré syndrome (GBS).

38 . The method according to claim 33 , wherein IL-17F is:

(a) a polypeptide comprising SEQ ID NO: 1;

(b) a polypeptide comprising amino acids 11 to 163 of SEQ ID NO: 1;

(c) a polypeptide comprising amino acids 21 to 163 of SEQ ID NO: 1;

(d) a polypeptide comprising amino acids 31 to 163 of SEQ ID NO: 1;

(e) a polypeptide comprising amino acids 55 to 163 of SEQ ID NO: 1;

(f) a mutein of any of (a) to (e), wherein the amino acid sequence has at least 40% or 50% or 60% or 70% or 80% or 90% identity to at least one of the sequences in (a) to (e);

(g) a mutein of any of (a) to (e) which is encoded by a DNA sequence which hybridizes to the complement of the native DNA sequence encoding any of (a) to (e) under moderately stringent conditions or under highly stringent conditions;

(h) a mutein of any of (a) to (e) wherein any changes in the amino acid sequence are conservative amino acid substitutions to the amino acid sequences in (a) to (e); or

(i) a salt or an isoform, fused protein, functional derivative, active fraction or circularly permutated derivative of any of (a) to (e).

39 . The method according to claim 33 , wherein IL-17F is dimeric.

40 . The method according to claim 38 , wherein IL-17F is fused to a carrier molecule, a peptide or a protein that promotes the crossing of the blood brain barrier.

41 . The method according to claim 38 , wherein the IL-17F is PEGylated.

42 . The method according to claim 40 , wherein the fused protein comprises an immunoglobulin (Ig) fusion.

43 . The method according to claim 33 , wherein said composition further comprises an interferon and/or osteopontin and/or clusterin, for simultaneous, sequential, or separate use.

44 . The method according to claim 34 , wherein the interferon is interferon-β.

45 . The method according to claim 33 , wherein the IL-17F is administered in an amount of about 0.001 to 100 mg/kg of body weight, or about 0.01 to 10 mg/kg of body weight or about 9, 8, 7, 6, 5, 4, 3, 2 or 1 mg/kg of body weight or about 0.1 to 1 mg/kg of body weight.